Comparison of HPMC Inhalation-Grade Capsules and Their Effect on Aerosol Performance Using Budesonide and Rifampicin DPI Formulations.

"Declarations Conflict of InterestHugh D. C. Smyth, one of the paper’s authors, works on inhaled product development for Respira Therapeutics, Via Therapeutics, Nob Hill Therapeutics, and Cloxero Therapeutics. The University of Texas at Austin has reviewed and approved the conditions of the agreement in accordance with its research objectivity policy. Ashlee Brunaugh owns stocks in both CloXero Therapeutics and Via Therapeutics companies. The University of Texas at Austin has reviewed and approved the conditions of the agreement in accordance with its research objectivity policy. Conflict of Interest Hugh D. C. Smyth, one of the paper’s authors, works on inhaled product development for Respira Therapeutics, Via Therapeutics, Nob Hill Therapeutics, and Cloxero Therapeutics. The University of Texas at Austin has reviewed and approved the conditions of the agreement in accordance with its research objectivity policy. Ashlee Brunaugh owns stocks in both CloXero Therapeutics and Via Therapeutics companies. The University of Texas at Austin has reviewed and approved the conditions of the agreement in accordance with its research objectivity policy."

"Funding The ACG North America/ACG Scitech Centre financially supported this study."